Atara Prices Secondary Offering to Raise $128 Million

Atara Biotherapeutics Inc. has priced its secondary stock offering to raise nearly $128 million, the company announced late Wednesday.

Monster Digital Extends Deadline for Reverse Merger

Monster Digital Inc. has extended to Jan. 26 the closing of its reverse merger with a North Carolina biopharmaceutical company.

Atara Proposes $100 Million Secondary Offering

Atara Biotherapeutics Inc. plans to raise $100 million through a secondary stock offering, the company announced Tuesday.

Atara Biotherapeutics Shares Rise on FDA Approval

Shares of Atara Biotherapeutics Inc. rose nearly 19 percent Friday after the company announced approval from the U.S. Food and Drug Administration to conduct Phase 3 clinical studies on its experimental drug tabelecleucel.

Amgen to Pay $6 Billion Tax Bill to Repatriate Cash

Amgen Inc. expects pay between $6 billion and $6.5 billion in taxes as it repatriates money from overseas operations, the company said Friday in a filing with the Securities and Exchange Commission.

AV Hospital Selects COO

Colette Menzel will assume the role of chief operating officer at Antelope Valley Hospital effective immediately, the hospital announced Wednesday.

Tease photo

Second Sight Stock Swings Up

Shares of Second Sight Medical Products Inc. made some major gains Tuesday, jumping more than 20 percent during trading hours before falling back to a nearly 18-percent gain by market close.

Sienna Biopharmaceuticals Names Advisory Board Members

Leading medical minds from Harvard, Massachusetts General Hospital, the University of Miami and other major institutions will lend their expertise to Sienna Biopharmaceuticals Inc. as members of its newly established corporate advisory board.

Eating Disorder Treatment Center Opens in Agoura Hills

A new treatment center for teenage girls with eating disorders has opened in Agoura Hills.

Amgen to Support FDA Approval for Biocartis Cancer Test

Amgen Inc. in Thousand Oaks has agreed to provide operational and financial support to Belgium-based Biocartis Group in its pursuit of Food and Drug Administration approval for a test that compliments Amgen’s metastatic colon cancer drug Vectibix, or panitumumab.

FDA Approves Label Expansion for Amgen's Repatha

The Food and Drug Administration has approved Amgen Inc.’s drug Repatha as a prevention for heart attacks in patients with cardiovascular disease, potentially enlarging the customer base for the drug.

Paralysis Partnership for Antelope Valley Hospital

The Antelope Valley Hospital has partnered with a local nonprofit to provide support to newly paralyzed patients.

Amgen Invests in Software Startup Syapse

Amgen Ventures, the investment arm of Thousand Oaks biopharmaceutical firm Amgen Inc., has invested an undisclosed sum in Syapse Inc., a San Francisco software company that has developed an integrative platform designed to streamline the “precision medicine” approach to cancer treatment.

Hospital-to-Home Clinic Opens in Sherman Oaks

Epic Medical Group has opened a clinic at Sherman Oaks Hospital to help close the gap between hospital stay and home for patients recovering from complex and chronic conditions, the company announced Thursday.

Amgen to Lay Off 121

Amgen Inc. will lay off up to 121 workers at its California sites beginning Dec. 31, according to a notice filed in early November with the California Employment Development Department.

Tease photo